Racial differences in COVID-19 severity associated with history of substance use disorders and overdose: Findings from multi-site electronic health records in New York City

[1]  N. Volkow,et al.  Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US , 2022, Molecular Psychiatry.

[2]  H. Pincus,et al.  COVID‐19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems , 2022, Addiction.

[3]  Janet S. Lee,et al.  Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study , 2022, Journal of General Internal Medicine.

[4]  Alex H. S. Harris,et al.  Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration , 2022, JAMA network open.

[5]  P. Muennig,et al.  Neighborhood disparities in COVID-19 outcomes in New York city over the first two waves of the outbreak , 2022, Annals of Epidemiology.

[6]  M. Alegría,et al.  Using a structural vulnerability framework to understand the impact of COVID‐19 on the lives of Medicaid beneficiaries receiving substance use treatment in New York City , 2022, Health services research.

[7]  Brandon D. L. Marshall,et al.  Forecasted and Observed Drug Overdose Deaths in the US During the COVID-19 Pandemic in 2020 , 2022, JAMA network open.

[8]  M. Olfson,et al.  Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records , 2022, Drug and Alcohol Dependence.

[9]  Joohyun Park,et al.  Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits – United States, April 2020–December 2020 , 2022, Drug and Alcohol Dependence.

[10]  A. M. Newman.  Moving beyond mistrust: Centering institutional change by decentering the white analytical lens. , 2021, Bioethics.

[11]  M. Bassett,et al.  Variation in COVID-19 Mortality in the US by Race and Ethnicity and Educational Attainment , 2021, JAMA network open.

[12]  W. Ongkeko,et al.  Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status , 2021, JAMA network open.

[13]  QuanQiu Wang,et al.  Increased risk for COVID‐19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021 , 2021, World psychiatry : official journal of the World Psychiatric Association.

[14]  B. Coull,et al.  On the Nature of Informative Presence Bias in Analyses of Electronic Health Records , 2021, Epidemiology.

[15]  Bryan Hartzler,et al.  Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19 , 2021, Journal of Substance Abuse Treatment.

[16]  Anna M. Acosta,et al.  Racial and Ethnic Disparities in Rates of COVID-19–Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021 , 2021, JAMA network open.

[17]  A. Flanagin,et al.  Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. , 2021, JAMA.

[18]  David A. Drew,et al.  Race, ethnicity, community-level socioeconomic factors, and risk of COVID-19 in the United States and the United Kingdom , 2021, EClinicalMedicine.

[19]  M. Leboyer,et al.  Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis , 2021, The Lancet Psychiatry.

[20]  G. Corbie-Smith.  Vaccine Hesitancy Is a Scapegoat for Structural Racism. , 2021, JAMA health forum.

[21]  S. Shiau,et al.  The Relationship Between Social Determinants of Health and Racial Disparities in COVID-19 Mortality , 2021, Journal of Racial and Ethnic Health Disparities.

[22]  Erin S. Rogers,et al.  Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January–October 2020 , 2020, Journal of public health.

[23]  S. Lipsitz,et al.  Derivation of a Clinical Risk Score to Predict 14-Day Occurrence of Hypoxia, ICU Admission, and Death Among Patients with Coronavirus Disease 2019 , 2020, Journal of General Internal Medicine.

[24]  Leora I. Horwitz,et al.  Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City , 2020, JAMA network open.

[25]  P. Austin,et al.  Missing Data in Clinical Research: A Tutorial on Multiple Imputation , 2020, The Canadian journal of cardiology.

[26]  M. J. Nguemeni Tiako,et al.  Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19 , 2020, Journal of Substance Abuse Treatment.

[27]  N. Volkow,et al.  COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States , 2020, Molecular Psychiatry.

[28]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[29]  Adolph Reed,et al.  Racial Health Disparities and Covid-19 - Caution and Context. , 2020, The New England journal of medicine.

[30]  H. Kunins.  Structural Racism and the Opioid Overdose Epidemic: The Need for Antiracist Public Health Practice , 2020, Journal of public health management and practice : JPHMP.

[31]  Changyu Shen,et al.  Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. , 2020, JAMA.

[32]  Julia Raifman,et al.  Disparities in the Population at Risk of Severe Illness From COVID-19 by Race/Ethnicity and Income , 2020, American Journal of Preventive Medicine.

[33]  B. Marshall,et al.  Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States , 2020, JAMA network open.

[34]  P. Seth,et al.  Drug and Opioid-Involved Overdose Deaths — United States, 2017–2018 , 2020, MMWR. Morbidity and mortality weekly report.

[35]  Wura Jacobs,et al.  Health Disparities and the Heterogeneity of Blacks/African Americans in the United States: Why Should We Care? , 2019, Health promotion practice.

[36]  H. Kunins,et al.  Racial Differences in Opioid Overdose Deaths in New York City, 2017 , 2019, JAMA internal medicine.

[37]  Lawrence Scholl,et al.  Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017 , 2018, MMWR. Morbidity and mortality weekly report.

[38]  J. Vandenbroucke,et al.  Effect modification, interaction and mediation: an overview of theoretical insights for clinical investigators , 2017, Clinical epidemiology.

[39]  L. Degenhardt,et al.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies , 2017, British Medical Journal.

[40]  D. N. Bertollo,et al.  Variation in Use of Buprenorphine and Methadone Treatment by Racial, Ethnic, and Income Characteristics of Residential Social Areas in New York City , 2013, The Journal of Behavioral Health Services & Research.

[41]  Karel G M Moons,et al.  Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis , 2012, Canadian Medical Association Journal.

[42]  Ayman Fareed,et al.  Effect of Methadone Maintenance Treatment on Heroin Craving, a Literature Review , 2010, Journal of addictive diseases.

[43]  Dennis Kao.  Factors Associated with Ethnic Differences in Health Insurance Coverage and Type Among Asian Americans , 2010, Journal of Community Health.

[44]  J. Rizzo,et al.  Heterogeneity in Health Insurance Coverage Among US Latino Adults , 2009, Journal of General Internal Medicine.

[45]  J. van Loon.  Network , 2006 .

[46]  S. Lange,et al.  Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.

[47]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .